Skip to main content
Fig. 2 | BMC Psychiatry

Fig. 2

From: Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials

Fig. 2

Time schedule of enrolment, interventions, and assessments. Crosses (X) indicate research steps to be conducted. Underlined crosses (X) indicate assessments via phone calls. ABC, Aberrant Behavior Checklist; ADAMS, Anxiety, Depression, and Mood Scale; CBD, cannabidiol; CGI, Clinical Global Impression; EEG, electroencephalogram; GAS, Goal Attainment Scaling; OBVL, parenting stress questionnaire; PedsQL, Pediatric Quality of Life Inventory; PQ, personal questionnaire; SCQ, Social Communication Questionnaire; SSP, Short Sensory Profile; SRS-2, Social Responsiveness Scale; VABS-III, Vineland Adaptive Behavior Scale-III

Back to article page

BMC Psychiatry

ISSN: 1471-244X

Contact us